These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 16705366)

  • 1. Predictors of reduced dose intensity in patients with early-stage breast cancer receiving adjuvant chemotherapy.
    Shayne M; Crawford J; Dale DC; Culakova E; Lyman GH;
    Breast Cancer Res Treat; 2006 Dec; 100(3):255-62. PubMed ID: 16705366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices.
    Lyman GH; Dale DC; Crawford J
    J Clin Oncol; 2003 Dec; 21(24):4524-31. PubMed ID: 14673039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose intensity and hematologic toxicity in older cancer patients receiving systemic chemotherapy.
    Shayne M; Culakova E; Poniewierski MS; Wolff D; Dale DC; Crawford J; Lyman GH
    Cancer; 2007 Oct; 110(7):1611-20. PubMed ID: 17705197
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study.
    Lyman GH; Dale DC; Friedberg J; Crawford J; Fisher RI
    J Clin Oncol; 2004 Nov; 22(21):4302-11. PubMed ID: 15381684
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Febrile neutropenia incidence and hematological toxicity with the FEC100-docetaxel regimen in the treatment of early-stage breast cancer.
    Cousin S; Le Rhun E; Mailliez A; Fournier C; Bonneterre J
    Bull Cancer; 2012; 99(7-8):75-80. PubMed ID: 22713627
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy.
    Hershman D; Neugut AI; Jacobson JS; Wang J; Tsai WY; McBride R; Bennett CL; Grann VR
    J Natl Cancer Inst; 2007 Feb; 99(3):196-205. PubMed ID: 17284714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence of reduced chemotherapy relative dose intensity among women with early stage breast cancer in US clinical practice.
    Weycker D; Barron R; Edelsberg J; Kartashov A; Lyman GH
    Breast Cancer Res Treat; 2012 May; 133(1):301-10. PubMed ID: 22270932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A retrospective evaluation of chemotherapy dose intensity and supportive care for early-stage breast cancer in a curative setting.
    Lyman GH; Dale DC; Tomita D; Whittaker S; Crawford J
    Breast Cancer Res Treat; 2013 Jun; 139(3):863-72. PubMed ID: 23771731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimal delivery of anthracycline-based chemotherapy in the adjuvant setting improves outcome of breast cancer patients.
    Chirivella I; Bermejo B; Insa A; Pérez-Fidalgo A; Magro A; Rosello S; García-Garre E; Martín P; Bosch A; Lluch A
    Breast Cancer Res Treat; 2009 Apr; 114(3):479-84. PubMed ID: 18463977
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer.
    Pinder MC; Duan Z; Goodwin JS; Hortobagyi GN; Giordano SH
    J Clin Oncol; 2007 Sep; 25(25):3808-15. PubMed ID: 17664460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of neutropenia on delivering planned chemotherapy for solid tumours.
    Khan S; Dhadda A; Fyfe D; Sundar S
    Eur J Cancer Care (Engl); 2008 Jan; 17(1):19-25. PubMed ID: 18181887
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patterns of toxicity in older patients with breast cancer receiving adjuvant chemotherapy.
    Hurria A; Brogan K; Panageas KS; Pearce C; Norton L; Jakubowski A; Zauderer M; Howard J; Hudis C
    Breast Cancer Res Treat; 2005 Jul; 92(2):151-6. PubMed ID: 15986124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pegfilgrastim administered on the same day with dose-dense adjuvant chemotherapy for breast cancer is associated with a higher incidence of febrile neutropenia as compared to conventional growth factor support: matched case-control study of the Hellenic Cooperative Oncology Group.
    Skarlos DV; Timotheadou E; Galani E; Samantas E; Grimani I; Lianos E; Aravantinos G; Xanthakis I; Pentheroudakis G; Pectasides D; Fountzilas G
    Oncology; 2009; 77(2):107-12. PubMed ID: 19622901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of new European Organisation for Research and Treatment of Cancer guidelines on the use of granulocyte colony-stimulating factor on the management of breast cancer patients.
    Zielinski CC; Awada A; Cameron DA; Cufer T; Martin M; Aapro M
    Eur J Cancer; 2008 Feb; 44(3):353-65. PubMed ID: 18191396
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of severe and febrile neutropenia during primary chemotherapy for ovarian cancer.
    Laskey RA; Poniewierski MS; Lopez MA; Hanna RK; Secord AA; Gehrig PA; Lyman GH; Havrilesky LJ
    Gynecol Oncol; 2012 Jun; 125(3):625-30. PubMed ID: 22426251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch Randomized Phase III Study.
    Timmer-Bonte JN; de Boo TM; Smit HJ; Biesma B; Wilschut FA; Cheragwandi SA; Termeer A; Hensing CA; Akkermans J; Adang EM; Bootsma GP; Tjan-Heijnen VC
    J Clin Oncol; 2005 Nov; 23(31):7974-84. PubMed ID: 16258098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose intensity and hematologic toxicity in older breast cancer patients receiving systemic chemotherapy.
    Shayne M; Culakova E; Wolff D; Poniewierski MS; Dale DC; Crawford J; Lyman GH
    Cancer; 2009 Nov; 115(22):5319-28. PubMed ID: 19672945
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of five prophylactic filgrastim schedules on hematologic toxicity in early breast cancer patients treated with epirubicin and cyclophosphamide.
    Papaldo P; Lopez M; Marolla P; Cortesi E; Antimi M; Terzoli E; Vici P; Barone C; Ferretti G; Di Cosimo S; Carlini P; Nisticò C; Conti F; Di Lauro L; Botti C; Di Filippo F; Fabi A; Giannarelli D; Calabresi F
    J Clin Oncol; 2005 Oct; 23(28):6908-18. PubMed ID: 16129844
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients.
    Ryberg M; Nielsen D; Cortese G; Nielsen G; Skovsgaard T; Andersen PK
    J Natl Cancer Inst; 2008 Aug; 100(15):1058-67. PubMed ID: 18664656
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Febrile neutropenia and related complications in breast cancer patients receiving pegfilgrastim primary prophylaxis versus current practice neutropaenia management: results from an integrated analysis.
    von Minckwitz G; Schwenkglenks M; Skacel T; Lyman GH; Pousa AL; Bacon P; Easton V; Aapro MS
    Eur J Cancer; 2009 Mar; 45(4):608-17. PubMed ID: 19110415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.